Literature DB >> 34129484

A Resident-Led Intervention to Increase Initiation of Buprenorphine Maintenance for Hospitalized Patients With Opioid Use Disorder.

Ashish P Thakrar1, David Furfaro2, Sara Keller3, Ryan Graddy4, Megan Buresh1, Leonard Feldman5.   

Abstract

BACKGROUND: Hospitalized patients with opioid use disorder (OUD) are rarely started on buprenorphine or methadone maintenance despite evidence that these medications reduce all-cause mortality, overdoses, and hospital readmissions.
OBJECTIVE: To assess whether clinician education and a team of residents and hospitalist attendings waivered to prescribe buprenorphine increased the rate of starting patients with OUD on buprenorphine maintenance. DESIGN, SETTING, AND PARTICIPANTS: Quality improvement study conducted at a large, urban, academic hospital in Maryland involving hospitalized patients with OUD on internal medicine resident services. INTERVENTION: We developed a protocol for initiating buprenorphine maintenance, presented an educational conference, and started the resident-led Buprenorphine Bridge Team of residents and attendings waivered to prescribe buprenorphine to bridge patients from discharge to follow-up. MEASUREMENTS: The percent of eligible inpatients with OUD initiated on buprenorphine maintenance, 24 weeks before and after the intervention; engagement in treatment after discharge; and resident knowledge and comfort with buprenorphine.
RESULTS: The rate of starting buprenorphine maintenance increased from 10% (30 of 305 eligible patients) to 24% (64 of 270 eligible patients) after the intervention, with interrupted time series analysis showing a significant increase in rate (14.4%; 95% CI, 3.6%-25.3%; P = .02). Engagement in treatment after discharge was unchanged (40%-46% engaged 30 days after discharge). Of 156 internal medicine residents, 89 (57%) completed the baseline survey and 66 (42%) completed the follow-up survey. Responses demonstrated improved resident knowledge and comfort with buprenorphine.
CONCLUSION: Internal medicine resident teams were more likely to start patients on buprenorphine maintenance after clinician education and implementation of a Buprenorphine Bridge Team.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34129484      PMCID: PMC8191766          DOI: 10.12788/jhm.3544

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.899


  24 in total

1.  Veterans Affairs facility performance on Washington Circle indicators and casemix-adjusted effectiveness.

Authors:  Alex H S Harris; Keith Humphreys; John W Finney
Journal:  J Subst Abuse Treat       Date:  2007-04-02

2.  Geographic location of buprenorphine-waivered physicians and integration with health systems.

Authors:  Brendan Saloner; LeeKai Lin; Kosali Simon
Journal:  J Subst Abuse Treat       Date:  2020-05-12

Review 3.  Treatment of Opioid-Use Disorders.

Authors:  Marc A Schuckit
Journal:  N Engl J Med       Date:  2016-07-28       Impact factor: 91.245

4.  Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder.

Authors:  Karen Crotty; Kenneth I Freedman; Kyle M Kampman
Journal:  J Addict Med       Date:  2020 Mar/Apr       Impact factor: 3.702

5.  Missed Opportunities for Treatment of Opioid Use Disorder in the Hospital Setting: Updating an Outdated Policy.

Authors:  Justin Berk; Kendall M Rogers; Deanna J Wilson; Ashish Thakrar; Leonard Feldman
Journal:  J Hosp Med       Date:  2020-10       Impact factor: 2.960

6.  Comparison between buprenorphine provider availability and opioid deaths among US counties.

Authors:  Christopher W Jones; Zachary Christman; Christopher M Smith; Michelle R Safferman; Matthew Salzman; Kaitlan Baston; Rachel Haroz
Journal:  J Subst Abuse Treat       Date:  2018-07-20

7.  Suboptimal Addiction Interventions for Patients Hospitalized with Injection Drug Use-Associated Infective Endocarditis.

Authors:  Elana S Rosenthal; Adolf W Karchmer; Jesse Theisen-Toupal; Roger Araujo Castillo; Chris F Rowley
Journal:  Am J Med       Date:  2015-11-18       Impact factor: 4.965

8.  Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002-12.

Authors:  Matthew V Ronan; Shoshana J Herzig
Journal:  Health Aff (Millwood)       Date:  2016-05-01       Impact factor: 6.301

9.  Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis.

Authors:  Honora Englander; Konrad Dobbertin; Bonnie K Lind; Christina Nicolaidis; Peter Graven; Claire Dorfman; P Todd Korthuis
Journal:  J Gen Intern Med       Date:  2019-12       Impact factor: 5.128

10.  Predictors of timely opioid agonist treatment initiation among veterans with and without HIV.

Authors:  Jessica J Wyse; Jonathan L Robbins; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Julie R Gaither; Kirsha Gordon; Melissa Skanderson; Declan T Barry; Stephen Crystal; Amy Justice; Kevin L Kraemer
Journal:  Drug Alcohol Depend       Date:  2019-03-09       Impact factor: 4.852

View more
  3 in total

Review 1.  A Taxonomy of Hospital-Based Addiction Care Models: a Scoping Review and Key Informant Interviews.

Authors:  Honora Englander; Amy Jones; Noa Krawczyk; Alisa Patten; Timothy Roberts; P Todd Korthuis; Jennifer McNeely
Journal:  J Gen Intern Med       Date:  2022-05-09       Impact factor: 6.473

2.  Implementation of a comprehensive hospitalist-led initiative to improve care for patients with opioid use disorder.

Authors:  Dana Clifton; Noel Ivey; Stephanie Poley; Amy O'Regan; Sudha R Raman; Nicole Frascino; Shavone Hamilton; Noppon Setji
Journal:  J Hosp Med       Date:  2022-05-10       Impact factor: 2.899

3.  Beyond opioid prescribing: Evaluation of a substance use disorder curriculum for OBGYN residents.

Authors:  Caitlin E Martin; Bhushan Thakkar; Lauren Cox; Elisabeth Johnson; Hendrée E Jones; AnnaMarie Connolly
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.